Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by jordon3on Jan 21, 2018 3:44pm
363 Views
Post# 27404237

A take on the Blanco Report

A take on the Blanco Report

Solving Ray Blanco's “Alzheimer's Disease is Now Completely ...

https://www.stockgumshoe.com/reviews/...alert/...ray-blancos.../comment-page-1/ 
  1.  
1 day ago - Ray Blanco calls their technology a “revolutionary 'prion targeting' protocol,” and these are the hints he drops about the company: “A scientific breakthrough so ... This is, Thinkolator sez, the little Canadian biotech ProMIS Neurosciences (PMN in Toronto, ARFXF OTC in the US). And I'm not going to dig ...
 
 I found this article interesting on three accounts
 
 
 He actually names  ProMis which was pretty obvious -------."So who is it? This is, Thinkolator sez, the little Canadian biotech ProMIS Neurosciences (PMN in Toronto, ARFXF OTC in the US)."
 
He suggest what the FEB 14 date maybe about.  
"So yes, the company will likely have a quarterly report around February 14, but the most aggressive thing likely from that is some update to their timeline for applying to start Phase 1 trials (the IND application) at some point over the next year or so, or, perhaps some optimistic commentary about partnering with a larger company."
 
He closed the article with.       " P.S. This isn’t the first time Blanco’s attention has been poured on an Alzheimer’s Disease stock — back in 2015 his teaser ad promises of a breakthrough, similar in tone to this ad, helped Anavex (AVXL) go from $5 to $15 in a matter of a week or so, though it came sharply back down when the reality of long-term clinical trials hit the stock. AVXL was far more advanced, of course, they were in Phase 2 trials at the time."
 
Just some thoughts to ponder.  Hoping Feb 14 is significant and not just BS from Blanco

glta J

Bullboard Posts